menu
    • menu
    [{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"European Biomedical Research Institute of Salerno","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ European Biomedical Research Institute of Salerno","highestDevelopmentStatusID":"6","companyTruncated":"9 Meters Biopharma \/ European Biomedical Research Institute of Salerno"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"RDD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Merger","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ RDD Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovate Biopharmaceuticals \/ RDD Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Larazotide Acetate

    Menu

    Larazotide Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Suppo...

                            Details : This study follows a Phase 2 clinical trial in 342 adult patients with celiac disease who had been on a gluten-free diet for at least 12 months, which concluded that INN-202 (larazotide) 0.5 mg significantly reduced symptoms of celiac disease.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            June 21, 2022

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : European Biomedical Research Institute of Salerno

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            9 Meters Biopharma Announces Agreement with EBRIS to Continue Evaluation of Larazotide for COVID-19 Respirator...

                            Details : EBRIS and 9 Meters have entered into a material transfer agreement for drug supply sufficient to initiate and complete a Phase 1 study in Australia in 2021 to assess the safety and tolerability of larazotide when delivered directly to the lungs.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            December 21, 2020

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : European Biomedical Research Institute of Salerno

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            9 Meters Biopharma Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Res...

                            Details : U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent for Use of Tight Junction Antagonists in the Treatment of Acute Lung Injury and Acute Respiratory Distress, relating to its proprietary investigational agent, larazotide.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            July 28, 2020

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            9 Meters Biopharma, Inc. Amends Definition of Primary Endpoint for Phase 3 Trial in Celiac Disease After Consu...

                            Details : The trial is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of larazotide for patients with celiac disease who continue to experience gastrointestinal symptoms while following a gluten-free diet.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            June 29, 2020

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : RDD Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Innovate Biopharmaceuticals and RDD Pharma Merge to Form 9 Meters Biopharma

                            Details : Innovative to change its name to 9 Meters Biopharma. 9 Biopharma meters to focus on delivering novel approach including the first and only long-acting GLP-1 agonist receptor for Short Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            April 30, 2020

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : RDD Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            June 26, 2018

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Amicus Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Amicus Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Fu...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 21, 2012

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            July 18, 2011

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth